Abstract Myeloperoxidase (MPO) is an oxidant generating enzyme normally restricted to myeloid cells, however aberrant MPO expression has been found to occur in non-myeloid cells in some disease states. The functional -463GA promoter polymorphism alters MPO expression levels. The -463G is within an SP1 binding site and is associated with higher gene expression. The G allele is most frequent with~62 % of European populations being GG homozygotes. The GA polymorphism has been associated with risk or survival in a variety of cancers including lung and breast cancer. In this study we determined the frequency of the -463G/A polymorphism in 230 ovarian cancer patients, 75 patients with borderline ovarian tumors, and 299 healthy controls. The GG genotype was found to be overrepresented in patients with early stage ovarian cancer (83.3 % GG, p =0.008) as compared to healthy controls (62 % GG), suggesting that MPO oxidants may increase risk. Immunohistochemical analysis revealed MPO expression in a subset of columnar ovarian epithelial carcinoma cells in early stage carcinomas.
Introduction
Ovarian cancer is the fourth most common cancer in women. While mutations in BRCA1 and BRCA2 are risk factors for familial ovarian cancer, the causal agents for sporadic ovarian cancers, representing the majority of cases, are relatively unknown [1] [2] [3] [4] . Higher numbers of lifetime ovulations are one risk factor, reflecting the cell division required to repair the recurrent disruption of the ovarian epithelial layer. Reactive oxygen species generated by inflammatory cells at sites of ovulation have been suggested to lead to DNA mutations increasing cancer risk [5] [6] [7] . The process of ovulation is accompanied by the infiltration of neutrophils and monocyte-macrophages in the follicle wall, theca, and corpus luteum. These cells release inflammatory cytokines and oxidizing agents including myeloperoxidase (MPO). MPO is present at high levels in neutrophils and monocytes, and catalyzes reactions with hydrogen peroxide and chloride to produce hypochlorous acid (HOCl), a potent microbicidal agent that damages DNA, proteins, and lipids [8] [9] [10] [11] [12] . MPO also generates chloramines, reactive nitrating agents and free radicals leading to lipid peroxidation [13, 14] . MPO expression is normally restricted to myeloid precursors, however recent studies have found aberrant expression of MPO in mature macrophages in atherosclerosis [15] and some nonmyeloid cells in neurodegenerative diseases [13, 15, 16] . This atypical expression can lead to oxidative damage to normal tissues contributing to atherosclerosis [13, 17, 18 ], Alzheimer's disease [16, 19] , and some types of cancer [20] .
Earlier studies have also found evidence implicating MPO in the initiation or progression of ovarian cancer [21] [22] [23] .
MPO has been linked to risk or outcome for a variety of cancer types through association of the -463G/A promoter polymorphism [20, [24] [25] [26] [27] [28] [29] [30] [31] . This polymorphism (rs2333227) is situated 463 bp upstream of the transcription initiation site within a primate-specific Alu element that encodes several sites recognized by SP1 and members of the nuclear receptor superfamily of transcription factors including estrogen receptor (ER), retinoic acid receptor (RAR), and peroxisome proliferator activated receptor (PPARα/γ) [32] [33] [34] . The -463G site enhances binding by Sp1 while -463A enhances binding by ER [33] [34] [35] . The G allele is several-fold higher expressing than the A allele [33, 34, 36] and the GG genotype is most frequent at 48-65 % of European or American populations [19, 20, 29] . The higher expressing GG genotype has been associated with increased risk for a number of types of cancer [20, 37] . A recent meta-analysis of breast cancer studies, including 2,975 cases and 3,427 controls, associated the AA genotype with significantly decreased risk for breast cancer in pre-menopausal women (OR=0.56, p =0.03) [25] , thereby associating the higher expressing GG genotype with increased risk. Conversely, in two studies, the GG genotype enhanced survival in early stage breast cancer patients undergoing chemotherapy. Patients with the G allele (GG or GA) had more than a 2-fold reduction in risk of recurrence or death [27, 28] . These studies suggest that MPO can both promote breast cancer through DNA damage while enhancing the tumoricidal activities of chemotheraputic drugs.
In a study of ovarian cancer patients, the lower expressing A allele (GA/AA genotypes) was previously found to be associated with a small reduction in risk (OR=0.72) although this trend did not reach statistical significance [22] . Other studies have found higher levels of MPO in gynaecological or ovarian cancer tissue [21, 23, 38] as well as evidence that MPO promotes nitrosylation of caspase-3, potentially inhibiting apoptosis and enhancing survival of ovarian cancer cells [21] .
These studies raise the possibility that MPO generated oxidants affect incidence or progression of ovarian cancer. In this study, we investigated the expression of MPO in ovarian cancer tissue and the association of the -463GA polymorphism with cancer incidence. The findings show that MPO is robustly expressed in a subset of ovarian carcinoma cells, and that the higher expressing GG genotype is overrepresented in early stage (FIGO I) cancer. and Obstetrics (FIGO) by pathologists in the corresponding institutions. Briefly, FIGO stage 1 is limited to one or both ovaries; stage II is limited to the uterus and pelvic structures; stage III includes extension to the small bowel or omentum; stage IV includes distant metastases to the liver or outside the peritoneal cavity. Only epithelial ovarian carcinomas of serous, mucinous, or endometrioid histological type were involved in this study. Patients underwent hysterectomy, bilateral salpingo-oophorectomy, pelvic and/or paraaortic lymphadenectomy, appendectomy, or omentectomy. All patients with FIGO stage Ic to IV received a platinum-based chemotherapy. All patients were followed up with vaginal and rectal palpation, serum marker evaluation, and vaginal cytology in a 3-month interval and abdominal CT scan in a 12-month interval. Whenever possible, recurrence was proven histologically or otherwise indicated by X-ray, computer tomography and/or tumor markers as measurable disease. The median observation time was 67 months. All procedures were approved by the responsible institutional ethical committees.
Materials and methods

Samples
DNA preparation and genotyping of MPO polymorphism
The G/A polymorphism at −463 of the MPO gene (rs2333227) was determined by digestion of a polymerase chain reaction (PCR)-amplified DNA fragment with Aci1 restriction enzyme that cuts at the G site [19, 26] . A confirmatory method was pyrosequencing using a Pyrosequencer PSQ 96 and the PSQ 96 SNP Reagent Kit (Uppsala, Sweden). DNA was isolated from blood using commercial kits (DNA Extraction System I; ViennaLab, Vienna, Austria). The primers MPO-SE 5′-ATCTTGGGCTGGTAGTGC-3′ and MPO-AS 5′-CCACATC ATCAATTATTTCC-3′ were used to amplify a 238-bp fragment of the MPO gene (GenBank accession no. M19507). MPO-SE was biotinylated. PCR was carried out in a total volume of 25 μl including 25 ng template, 5 pmol of each sense and antisense primers and puReTaq Ready-To-Go PCR Beads (Amersham Biosciences UK Limited, UK), which contain 2.5 units of puReTaq DNA polymerase, 10 mM Tris-HCl (pH 9.0 at room temperature), 50 mM KCl, 1.5 mM MgCl 2 , 200 μM dATP, dCTP, dGTP and dTTP, and stabilizers, including BSA. PCR was performed on a Perkin-Elmer GeneAmp PCR system 9600 with 40 cycles at 94°C for 30 s, at 51°C for 30 s and 72°C for 30 s. The reaction was preceded by a primary denaturation step at 94°C for 1 min and finally incubated at 72°C for 7 min. First, 25 μl of the PCR product was used for pyrosequencing according to the instruction of the manufacturer. Then, 5 pmol of the sequencing primer MPO-SEQ 5′-CCTCAAGTGATCCACC-3′ was applied to detect the polymorphism.
Statistical analysis
Association of genotypes with histological type, differentiation grade, FIGO stage and nodal status of the ovarian malignancies and age of the patients, which was dichotomized at 50 years, was assessed using the Chi-square test. Genotype distributions and allele frequencies were compared between patients with ovarian malignancies and healthy women using the Chi-square test. In all analyses, the Chi-square test was replaced by Fisher's exact test whenever an expected cell frequency was lower than 5. In either subpopulation, violations of the Hardy-Weinberg assumptions were statistically tested by comparing the observed genotype distribution with that expected under the HardyWeinberg equilibrium, using an exact permutation test. The 95 % confidence intervals (CI) for allele frequencies are based on 10,000 bootstrap resamples of individuals. The association of MPO genotypes with the risk of nodal involvement was expressed as odds ratio (OR), estimated by exact conditional logistic regression. These ORs were computed for the additive (allele-dose) model, and the dominance (carrier vs. non-carrier) models. The 95 % CI for the OR were computed using the mid-P method. Disease-free survival is defined as time between diagnosis of disease and recurrence or distant metastasis. Overall survival is defined as the time from diagnosis of disease to death of a patient. The association of MPO genotype with disease-free survival and overall survival was assessed by estimating survival curves through the Kaplan-Meier method [20] , which was compared by the log-rank test. The Cox regression model [21] was used to estimate crude hazard ratios and hazard 
Results
Analysis of myeloperoxidase expression in ovarian cancer cells
Immunohistochemical analysis of ovarian cancer tissue revealed robust levels of MPO expression in some of the ovarian cancer cells. Confocal images of FIGO stage 1 ovarian carcinoma detected MPO in columnar epithelial carcinoma cells (Fig. 1a) that were clearly distinct from nearby CD68-positive monocyte-macrophages which lacked MPO. In the same tumor, MPO was similarly detected in epithelial cancer cells in the absence of adjacent CD68-positive macrophage-monocytes (Fig. 1b) . Detection of MPO in ovarian cancer cells was unexpected because MPO protein is normally restricted to myeloid cells, including neutrophils, monocytes and some reactive macrophages [10, 15] . In other regions of this tumor, MPO colocalized with CD68 in macrophages infiltrating the epithelial layers (Fig. 1c) , indicating MPO expression can be induced in some macrophages closely associated with ovarian cancer cells. Appropriate controls showed no staining in the absence of primary antibodies or presence or irrelevant primary antibodies (Fig. 1d-f) . In borderline tumors, MPO was similarly expressed in a subset of epithelial cells in papillary formations, and was found to be strongly expressed in papillary regions undergoing loss of epithelial organization (Fig. 1g,h ). In advanced serous carcinomas (FIGO stage III), MPO was present at high levels in regions containing ovarian cancer cells as well as infiltrating neutrophils and monocytes (Fig. 1i) . Overall, these findings clearly show that MPO can be expressed in subsets of ovarian cancer cells in early to later stage tumors, raising the possibility that MPO oxidants could impact tumor cell growth and survival.
Determination of association of the -463GA MPO promoter polymorphism with ovarian cancer cases and controls One means to gain information as to the effects of MPO expression levels on ovarian cancer is to determine the frequencies of the -463GA promoter polymorphism. This is a functional polymorphism that has been demonstrated to alter gene expression levels and to be associated with risk for a number of cancers as well as atherosclerosis and neurodegenerative diseases [13, 15, 19, 35, 39] . Here, we compared the MPO genotype frequencies in patients with early to late clinical stages of ovarian cancer as defined by FIGO stages I to IV (Table 1) as well as borderline cases ( Table 2 ). The MPO genotype distribution was found to be significantly different with regard to FIGO stage. The percentage of GG genotype was higher in patients with early stage (FIGO I) as compared to patients with later stages (FIGO II to IV) (p =0.014; Table 1 ). Consistent with that finding, the GG genotype was more frequent in patients lacking lymph node involvement (72.2 %) than in patients with lymph node involvement (53.7 %, p =0.012; Table 3 ). The genotype distribution of FIGO I cases was also significantly different from borderline tumors (GG 57.3 %) (p =0.01) or healthy controls (GG 62.5 %) ( Table 4 ; p =0.024). Analysis of allelic frequencies showed the A-allele frequency for FIGO I stage carcinomas was 8 %, contrasting significantly with 22 % A allele in advanced FIGO stage II-IV cases (p =0.004), 23 % in borderline tumors (p =0.004), and 26 % in healthy controls Tables 1 and 4 ). There was no association of MPO genotype with histological type of cancer (serous, mucinous, or endometrioid), or age at diagnosis (Table 1) .
Discussion
These findings show that the higher expressing -463GG genotype is more frequent in FIGO I early stage carcinoma suggesting the G allele increases risk for ovarian cancer. These findings are consistent with an earlier study in which the lower expressing A allele was associated with reduced risk for ovarian cancer [22] , although that finding did not reach statistical significance. Together these studies suggest the atypical expression of this normally myeloid-specific MPO gene in ovarian epithelial cells could lead to oxidation damage and mutations that increase risk of cancer. The higher expressing GG genotype was not overrepresented in later stage II-IV cancers. Current models of ovarian cancer propose that early grade (Type I) and high grade (Type II) ovarian carcinomas are distinct diseases, arising by different genetic mutations [2, 40] . Type I carcinomas are more often associated with KRAS and BRAF mutations, while Type II carcinomas tend to have mutations in p53 and BRCA1/2 genes [2] . Type I carcinomas appear to develop in incremental steps from borderline adenomas, while Type II cancers appear to arise from the epithelium as a rapidly growing cancer without a precursor state. If Types I and II are distinct diseases, this could explain why the GG genotype is associated with early but not later stages. A second possible explanation is that higher MPO expression in early stage GG carcinomas results in oxidative damage that impairs cell survival, such that fewer GG cancer cells survive to advanced stages. As a third possibility, higher levels of MPO in invading GG neutrophils and monocytemacrophages could promote the killing of early stage cancer cells, reducing the number of GG cases that advance to stages II-IV.
The finding of MPO in a subset of clearly defined epithelial carcinoma cells was unexpected. A prior study detected MPO in ovarian cancer tissue in low magnification images of low resolution in which the localization of MPO in individual cells was unclear [21] . Our confocal studies shown here reveal discrete expression in subsets of epithelial cancer cells rather than uniform overall expression. MPO is detected in early carcinoma cells as well as in distinct focal areas in borderline and advanced stage cancers. These findings are consistent with prior studies showing that the human MPO gene can be aberrantly expressed in subsets of non-myeloid cells in disease states such as Alzheimer's and Parkinson's disease [13, 16, 19, 41] .
The association of the higher expressing MPO GG genotype with greater risk for early stage ovarian cancer is consistent with DNA damage. MPO is known to create oxidants that damage DNA. The major MPO product, HOCl, results in oxidation of pyrimidine bases and chlorination of cytosine in bronchial epithelial cells [42] . MPO is involved in the bioactivation of inhaled polycyclic aromatic hydrocarbons to generate DNA binding metabolites that are mutagenic [43, 44] . HOCl inhibits repair of DNA strand breaks and nucleotide excision [45] [46] [47] . The detection of higher levels of MPO in cancer tissue is consistent with a role in carcinogenesis. Patients with colorectal tumors were found to have a higher number of MPO-positive cells in normal mucosa than did controls [48, 49] . Ovarian cancer tissue was found to have higher MPO levels than benign growths or inflammatory tissue [23] . Serum MPO levels were also found to be higher in stage II-IV ovarian cancer cases [23] . Consistent with the association of higher levels of MPO with cancer risk, the higher expressing MPO G allele has been linked to increased risk for a number of cancers including lung [24, 31, 50, 51] , breast [28, 52] , ovarian [22] , bladder [53] , larynx [29] , as well as myeloid leukemia [26] .
In summary, these studies provide evidence that MPO is atypically expressed in a subset of ovarian cancer cells. A second finding is that the higher expressing MPO GG genotype is associated with early stage carcinoma suggesting MPO oxidants increase cancer risk, consistent with an earlier study associating the low expressing A allele with reduced risk [22] . These findings are consistent with a model in which MPO oxidants damage DNA, thereby increasing risk of mutations promoting cancer. Further studies are needed to determine the role of MPO expression in ovarian cancer.
